G. P. Dimov

G. P. Dimov

Auto-generated profile, based on publicly available information

G. P. Dimov

Chelyabinsk City Clinical Hospital No. 1, Holder of the "Order of the Red Banner of Labor

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Clinical oncohematology
Verified
Journal Article
Open access
PDF file
TITatyana Ionova
Tatyana Ionova
AKAlexander Kulagin
Alexander Kulagin
ELE. A. Lukina
E. A. Lukina
VPV. V. Ptushkin
V. V. Ptushkin
EAE. G. Arshanskaya
E. G. Arshanskaya
TNTatyana Pavlovna Nikitina
Tatyana Pavlovna Nikitina
BACKGROUND. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired clonal non-neoplastic disorder of hematopoietic tissue characterized by complement-mediated hemolysis, bone marrow dysfunction, and higher risk of thrombotic and organic complications. This disease is associated with rapid rate of progression as well as worsening life expectancy and quality of life. Despite high efficacy of anti-complement treatment, a considerable proportion of patients show suboptimal response to pathogenetic therapy. Problems that patients encounter in everyday life, their quality of life, burden of disease, and limitations in professional life have not been adequately addressed in literature. AIM. To study sociomedical profile and quality-of-life indicators of PNH patients with suboptimal response to pathogenetic therapy and to assess the FACIT-Fatigue Scale in terms of its clinical information value and practical significance for analyzing the overall treatment success. MATERIALS & METHODS. As part of the multicenter observational clinical study, PNH patients with suboptimal response to pathogenetic therapy completed the EQ-5D and FACIT-Fatigue questionnaires as well as a checklist of main PNH symptoms, their disease, treatment, and professional life. The method of descriptive statistics as well as the Mann-Whitney test, the χ2 test, and correlation analysis were used to analyze the data. RESULTS. The study was based on the data from 45 PNH patients treated in 12 health centers in Russia (classic PNH accounted for 64.4 %). The age median was 41 years, 62 % of patients were women. The mean duration of suboptimal response to pathogenetic therapy was 3.2 years. Most patients had mobility issues (55.6 %), anxiety/depression (62.2 %), and hardships in their daily activities (68.9 %). In the vast majority of them, the disease had a moderate or considerable impact on their daily activities and social/family life. In 61 % of professionally active patients, the underlying disease moderately or considerably limited their professional life. Most patients reported fatigue (96 %), headache (86 %), dyspnea (83 %), concentration issues and sleep disorders (82 %), rapid heartbeat (77 %), yellowness of the skin (76 %), and back pain (71 %). Pronounced fatigue (with FACIT-Fatigue score of < 40) was registered in 70 % of patients. A significant correlation was established between FACIT-Fatigue and EQ-5D VAS scores as well as a relationship with the severity of dyspnea, tachycardia, and concentration loss. CONCLUSION. This clinical study demonstrated a considerably reduced quality of life of PNH patients with suboptimal response to pathogenetic therapy. It also confirmed the information value of the FACIT-Fatigue Scale for assessing fatigue and its impact on everyday life. This study clearly identified outstanding issues related to PNH patients with suboptimal response to pathogenetic therapy. That can contribute to bringing more patient-oriented care to this challenging population of hematologic patients.

30 September 2026 in Oncohematology
Verified
Journal Article
Open access
PDF file
BBB. A. Bakirov
B. A. Bakirov
БАБакиров Б. А.
Бакиров Б. А.
GDG. P. Dimov
G. P. Dimov
ДПДимов Г. П.
Димов Г. П.
ASA. A. Shutylev
A. A. Shutylev
КДКулагин А. Д.
Кулагин А. Д.
Background. Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening disease characterized by intravascular hemolysis, thrombosis, and bone marrow failure. The introduction of anti-C5 therapy (eculizumab, ravulizumab) has significantly improved patient outcomes; however, suboptimal hematological response, breakthrough hemolysis, and inadequate disease monitoring persist in real-world clinical practice. Data on the real-world management of PNH patients in the Russian Federation are limited, justifying the need for the present study. Aim. To evaluate the clinical and demographic characteristics, the rate and quality of hematological response, the frequency of laboratory monitoring, and the disease course features in PNH patients receiving or not receiving complement C5 inhibitors (anti-C5 therapy) in real-world clinical practice in the Russian Federation. Materials and methods. A retrospective, non-interventional study (RADAR-PNH) was conducted and included 145 adult patients with a confirmed diagnosis of PNH. The primary analysis assessed hematological response and the frequency of key disease parameters monitoring during the 12 months following anti-C5 therapy initiation (n = 128). Results. An optimal hematological response to anti-C5 therapy was achieved in 75 (58.6 %) of patients, including a complete response in 31 (24.2 %) and a good response in 44 (34.4 %). A suboptimal response persisted in 53 (41.4 %) of patients, including a minor response in 21 (16.4 %). Only 32 (25 %) of patients on anti-C5 therapy underwent complete regular laboratory monitoring. During the entire observation period, 43 (33.9 %) patients required red blood cell transfusions. Breakthrough intravascular hemolysis was reported in 30 (23.4 %) of patients. Five (3.9 %) patients developed thrombosis while receiving C5 inhibitor therapy. Conclusion. The obtained data indicate a substantial proportion of patients with an incomplete hematological response, inadequate laboratory monitoring, and a persistent risk of breakthrough hemolysis and thrombosis even during targeted therapy. This study may provide a basis for systemic improvements in the diagnosis, follow-up, and treatment of PNH aimed at enhancing the quality of life and prognosis in this patient population.